CD274 and hepatocellular carcinoma: It was proved that TME, specific receptors, and signaling pathways can affect the clinical outcome of PD-1/PD-L1 treatment (19), Combining different immunotherapies or combining immunotherapies with other modalities may provide synergistic effects and facilitate the development of the treatment of HCC (20).